Download PDF
Thromb Haemost 2013; 110(03): 496-500
DOI: 10.1160/TH13-03-0246
Pro/Contra Article
Schattauer GmbH

Contra: “New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation”

Claudia Stöllberger
1   Krankenanstalt Rudolfstiftung, Vienna, Austria
,
Josef Finsterer
1   Krankenanstalt Rudolfstiftung, Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received: 21 March 2013

Accepted after major revision: 07 June 2013

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151.
    CrossrefPubMedSearch in Google Scholar
  • 2 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891.
    CrossrefPubMedSearch in Google Scholar
  • 3 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011; 365: 981-992.
    CrossrefPubMedSearch in Google Scholar
  • 4 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
    CrossrefPubMedSearch in Google Scholar
  • 5 You JJ, Singer DE, Howard PA. et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-e575S.
    CrossrefPubMedSearch in Google Scholar
  • 6 Wann LS, Curtis AB, Ellenbogen KA. et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57: 1330-1337.
    CrossrefPubMedSearch in Google Scholar
  • 7 Heidbuchel H, Verhamme P, Alings M. et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013. Epub ahead of print
    CrossrefSearch in Google Scholar
  • 8 Ntaios G, Papavasileiou V, Diener HC. et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 3298-3304.
    CrossrefPubMedSearch in Google Scholar
  • 9 Easton JD, Lopes RD, Bahit MC. et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511.
    CrossrefPubMedSearch in Google Scholar
  • 10 Stöllberger C, Finsterer J. Concerns about storage and application of dabigatran and rivaroxaban. Eur J Clin Pharmacol 2013; 69: 739-740.
    CrossrefPubMedSearch in Google Scholar
  • 11 Lillo-Le Louët A, Wolf M, Soufir L. et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation. Thromb Haemost 2012; 08: 583-585.
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Hart RG, Diener HC, Yang S. et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517.
    CrossrefPubMedSearch in Google Scholar
  • 13 Mant J, Hobbs FD, Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
    CrossrefPubMedSearch in Google Scholar
  • 14 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
    CrossrefPubMedSearch in Google Scholar
  • 15 Matute MC, Guillán M, García-Caldentey J. et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106: 178-179.
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Stöllberger C, Rakusan S, Wimpissinger FT. et al. Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention. Thromb Haemost 2012; 108: 579-581.
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Höllerl F, Stöllberger C, Finsterer J. Renal function, P-gp-affecting drugs and new anticoagulants for stroke prevention. Int J Cardiol. 2013. Epub ahead of print
    CrossrefSearch in Google Scholar
  • 18 Hansen ML, Sørensen R, Clausen MT. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.
    CrossrefPubMedSearch in Google Scholar
  • 19 De Smedt A, De Raedt S, Nieboer K. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010; 30: 533-534.
    CrossrefPubMedSearch in Google Scholar
  • 20 Dhamoon MS, Tai W, Boden-Albala B. et al. Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke 2007; 38: 1752-1758.
    CrossrefPubMedSearch in Google Scholar
  • 21 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
    CrossrefPubMedSearch in Google Scholar
  • 22 Rose AJ, Hylek EM, Ozonoff A. et al. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes 2011; 04: 22-29.
    CrossrefPubMedSearch in Google Scholar
  • 23 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
    CrossrefPubMedSearch in Google Scholar
  • 24 Wallentin L, Lopes RD, Hanna M. et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation. 2013. Epub ahead of print
    Search in Google Scholar
  • 25 Heneghan C, Ward A, Perera R. et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322-334.
    CrossrefPubMedSearch in Google Scholar